We help you manage your most important asset - your relationships. Our product identifies the right people to contact, helps strengthen those relationships, and recommends ways to accomplish goals through your network. We achieve this by working with your email, calendar, and other data sources - and fusing that with our algorithms and the practices of the world's best relationship builders. In doing so, we empower you to develop your most powerful source of opportunity - knowing the right people.

Aer Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapeutic solutions for muco-obstructive lung diseases, particularly targeting conditions like COPD, cystic fibrosis, and asthma. Their lead product, AER-01, is a novel inhaled mucolytic agent designed to effectively liquefy mucus plugs, addressing a significant unmet medical need in patients suffering from airway obstruction. The company leverages advanced lung imaging techniques to identify patients with clinically silent mucus plugs and measure the efficacy of their treatments. With a strong foundation in research and development, supported by over $18M in NIH funding, Aer Therapeutics is positioned to make a substantial impact in the respiratory disease market.

Aeva is a technology company specializing in advanced sensing and perception systems for autonomous navigation. Their key products, Aeries II and Atlas, utilize innovative FMCW technology to provide 4D LiDAR sensors that detect velocity and range simultaneously, enhancing the decision-making capabilities of autonomous vehicles and robots. Aeva differentiates itself with automotive-grade sensors designed for mass production, aiming to revolutionize the autonomous mobility market. The company has secured significant contracts, including a $1 billion deal with Daimler Truck, positioning it as a leader in the autonomous sensing space.

Agomab Therapeutics is focused on developing innovative therapies to treat fibrosis and restore organ function across multiple therapeutic areas. Their pipeline includes AGMB-129, a small molecule inhibitor targeting fibrostenosing Crohn’s disease, AGMB-447 for idiopathic pulmonary fibrosis, and AGMB-101 for liver cirrhosis. The company differentiates itself through its expertise in growth factor biology and a commitment to biologically validated pathways, positioning itself strongly in the biopharmaceutical market. With a recent $89 million Series D financing, Agomab is well-equipped to advance its clinical development and expand its impact in treating fibrotic diseases.

Aim Security specializes in providing comprehensive security solutions for enterprises adopting generative artificial intelligence (AI). The company's platform is designed to address the unique security challenges posed by AI, including data exposure, supply chain vulnerabilities, and malicious outputs. Aim's offerings include AI-SPM and AI-Firewall, which help organizations secure their AI usage and mitigate risks in real-time. With a focus on compliance and data protection, Aim positions itself as a leader in the rapidly evolving AI security market, catering to enterprises looking to leverage AI safely and effectively.

Aireye is a next-generation Wi-Fi firewall platform that serves as a critical first line of defense for wireless security. It offers agentless, AI-driven, and SaaS solutions that protect IT and OT assets without isolating them from the network. Aireye's unique approach allows for continuous monitoring and real-time detection of unauthorized access and data leakage, making it essential for industries like healthcare and defense. With a projected growth in Wi-Fi assets and increasing vulnerabilities, Aireye positions itself as a leader in network airspace control, ensuring the protection of critical assets against evolving threats.

Theia is a healthtech company focused on providing respectful prenatal and childbirth care, emphasizing a coordinated approach with a multidisciplinary team. They offer services from pregnancy through the first year of a child's life, ensuring that mothers have access to a range of specialists and 24/7 support. Theia differentiates itself by prioritizing patient autonomy and evidence-based information, and it has seen significant growth, including a fivefold increase in revenue in 2021 and over a thousand consultations performed. The company has established partnerships with health plans, making their services accessible to a broader audience.

Alkymi is a software company that empowers financial services firms by unlocking the full value of private markets data through AI-powered automation. Founded in 2017 by a team from Bloomberg and Two Sigma, Alkymi transforms unstructured data from various sources into actionable insights, enabling businesses to accelerate decision-making and improve operational efficiency. Their platform supports multiple investment document workflows, allowing firms to manage capital notices, financial statements, and more in a single solution. With backing from notable investors like Intel Capital and Canaan, Alkymi is positioned as a leader in the financial data operations space, helping clients respond quickly to market changes and enhance their data quality.

Almanac is the most powerful platform for async collaboration. A modern doc editor with version control to manage changes across docs and automated workflows for reviews, revisions, and suggestions. Built to give innovative companies, distributed teams, and the world's most ambitious people power, organization, and transparency—so they can can collaborate with focus and speed. Join us in a world with less meetings and messages!

Alpaca is a tech start-up that helps both renters and landlords throughout the tedious journey of renting apartments. Its team has helped over 4 million roommates, renters, and landlords through the process of finding a home. Alpaca’s AI manages the largest network of housing Facebook groups in the world, active in over 200 cities. The company was founded in 2018 and is headquartered in Berlin, Germany.